Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Financial Performance and Operational Highlights
AMGN logo

Amgen's Net Income Soars 84% Year-to-Date Amid Pricing Pressures

AMGN10-QFiling Date: 11/5/2025
Amgen Inc.
Description

What this story covers

Amgen's Q3 2025 revenues rose 12% to $9.6B, driven by 14% volume growth in key therapies, offsetting price erosion. Net income surged 84% YTD to $6.4B, boosted by debt gains and equity appreciation. Portfolio highlights include Repatha's 40% jump; impairments hit Otezla. Strong liquidity supports R&D and dividends amid legal and policy risks.

Story snapshot

CompanyAmgen Inc.
TickerAMGN
VariantStandard detailed
Duration14:48
Filing type10-Q
PeriodQ3 2025
IndustryHealthcare & Pharmaceuticals
Accession0000318154-25-000072

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in